FDA Approves Rezurock (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)

FDA Approves Rezurock (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD) NEW YORK, NY / ACCESSWIRE / July 16, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezurock™ (belumosudil) 200 mg once daily (QD) for the treatment of adult and pediatric patients… Read More »

More Bad News for Masks

Read the Full Article for Free! Read the Full Article for Free! Daily Newsletter Weekly Newsletter (Every Monday) You can unsubscribe at any time and I guarantee the privacy of your email. View our privacy policy Subscribe for FREE to the #1 Natural Health Newsletter or Login for Instant Access Unlock censored health information that… Read More »